Work

Scientific and Regulatory Policy Committee Points to Consider*: Sample Selection, Assay Design, Data Generation and Interpretation, and Reporting Practices for Chromogenic Immunohistochemical (IHC) Assays in Nonclinical Drug Development

Year: 2025

Type: article

Source: Toxicologic Pathology

DOI: 10.1177/01926233251393154

Authors: Famke Aeffner, Brad Bolon, Molly H. Boyle, Bernard S. Buetow, Thomas Forest, Kyathanahalli Janardhan, Keith Mansfield, David K. Meyerholz, Shari Price, Marlon C. Rebelatto

Institutions: Amgen (United States), LabCorp (United States), Pfizer (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), University of Iowa, Charles River Laboratories (United States), AstraZeneca (United States)

Language: English

Topic: Immunotoxicology and immune responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7117775117

FWCI: 1.185

Cites: 116

Cited by: 4

Related to: